ICER to Perform Value-Assessment for KarXT Schizophrenia Treatment
The Institute for Clinical and Economic Review (ICER) will perform a value-assessment on KarXT (xanomeline tartrate/trospium chloride), Karuna Therapeutics’ experimental therapeutic for schizophrenia. Public discussion of the assessment will take place next February at the 2024 New England CEPAC meeting.
Schizophrenia caregivers – realizing the impact
Schizophrenia is a debilitating condition that makes it difficult for patients to perform routine daily tasks or hold a job. [...]
Advertisement
